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Introduction: Despite increasing use of tunneled pleural catheters
(TPCs), their efficacy as a definitive procedure for achieving palli-
ation or spontaneous pleurodesis (SP) in the management of malig-
nant pleural effusion (MPE) remains unclear. In the largest TPC
series to date, we evaluate the efficacy for palliation and review the
rate and predictors of SP.
Methods: Retrospective review of 418 TPCs (355 patients) over 2
years (September 2007–September 2009) was performed. Palliation
was deemed successful when the patient did not require any other
subsequent effusion-directed drainage procedure. SP was defined as
satisfying the following criteria: (a) TPC removal without need for
further effusion-directed intervention during the patient’s lifespan
and (b) no evidence of effusion reaccumulation by clinical and
radiographic evidence at 1-month postremoval follow-up.
Results: After TPC placement, no subsequent effusion-directed
procedure was required for 380 of 418 (91%). SP was achieved after
only 26% of TPCs (110 of 418), in which the median time to
catheter removal was 44 days. Neither demographics nor primary
tumor type predicted SP. In patients selected for TPC placement in
the operating room, SP occurred in 36% (39 of 107), with 45% in
loculated MPE (13 of 29, p  0.014). Complications occurred after
20 TPCs (4.8%), with none occurring after bedside placement.
Conclusion: TPC placement is safe and provides durable palliation,
most often obviating the need for subsequent procedures in MPE
patients. TPC, however, remains suboptimal at achieving pleurodesis.
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In patients with solid organ cancers, malignant pleural effu-sion (MPE) is a terminal condition affecting more than
150,000 patients each year in the United States alone.1 In
addition to a poor median survival of 3 to 12 months, onset of
MPE also diminishes quality of life and requires multiple
hospital admissions and interventions.2 The available treat-
ment options for MPE include thoracentesis, chemical pleu-
rodesis through chest tube or thoracoscopy, or tunneled
pleural catheters (TPCs). Among these modalities, a recent
systematic review from the Cochrane Database documents
chemical pleurodesis with talc as the optimal modality for
achieving pleurodesis, with reported rates more than 90%.3
However, in addition to achieving pleurodesis, a key objec-
tive in these terminally ill patients is palliation of symptoms
and optimizing quality of life while minimizing interventions
and hospital stay. Compared with talc pleurodesis by chest
tube, TPC has gained popularity as a less invasive, more
comfortable outpatient modality in MPE management, as
demonstrated by the five-fold increase in use at our institution
over the last 2 years. A similar trend is seen throughout the
country—an estimated 11,600 patients were treated with
TPCs 2 years ago in the United States; and today, approxi-
mately 39,000 TPCs are placed annually (personal commu-
nication, IMS 3Q 2009 Market Data). While its short-term
cost-effectiveness is proven,4 published spontaneous pleu-
rodesis (SP) rates by this modality vary across studies, rang-
ing from 21 to 76%.4–14 Moreover, due to a small number of
patients in many of these case series and a lack of a stringent
definition for SP, the role of TPC in achieving SP is unclear.
Herein, we review our experience of the largest TPC series to
date and report our rates of palliative efficacy and SP.
PATIENTS AND METHODS
Patient Population and Drainage Protocol
A retrospective review of our prospectively maintained
database was conducted to identify all patients who under-
went at least one TPC insertion at our institution from
September 2007 to September 2009. Approval for the study
was obtained from the Memorial Sloan-Kettering Cancer
Center Institutional Review Board. All patients who under-
went placement of TPC were included (procedures were
performed by interventional radiologists, thoracic surgeons,
surgical physician assistants under supervision of thoracic
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surgeons, or pulmonologists). On discharge, patients were
instructed to drain the vacuum bottle twice a day if the output
was 500 ml/d, once a day if 200 to 500 ml/d, and every
other day if 200 ml/d. When the drainage subsided to 50
ml/d on three consecutive drainages without radiographic
evidence of reaccumulation, the catheters were removed. No
sclerosing agent was administered though the catheter.
Patient and Procedure Characteristics
Collected data included patient demographics, primary
cancer site, previous ipsilateral effusion-directed procedures,
laterality of TPC insertion, location of TPC insertion (inter-
ventional radiology [IR], operating room [OR], bedside, or
clinic), day of TPC insertion and removal, and day of last
follow-up or death. For TPCs placed in the OR, operative
notes were reviewed to determine whether video-assisted
thoracic surgery (VATS) guidance and/or lysis of adhesions
occurred during placement of TPC. Other than VATS-guided
placement, TPCs were placed using a routine Seldinger
technique (pleural space is accessed with a hollow needle,
through which a guidewire is advanced; a sheath is passed
over the guidewire after needle withdrawal; after guidewire
withdrawal, the catheter is introduced through the sheath into
the pleural space). Preinsertion radiographic images (chest
computed tomography scan or chest radiograph when com-
puted tomography scan was not available) were reviewed to
characterize the effusion as simple or loculated. Follow-up
data included presence or absence of symptoms, effusion size
1 month after TPC removal as assessed by radiographic
images, need for additional effusion-directed procedures, and
TPC-related complications.
Definition
Palliation was deemed successful when the patient did
not require any other subsequent effusion-directed drainage
procedure. SP was deemed successful when a catheter met
the following criteria: (a) removal of the catheter without
further effusion-directed intervention during patient’s lifes-
pan and (b) no evidence of effusion reaccumulation by
clinical and radiographic evidence at 1-month postremoval.
Previous procedure was defined as an effusion-directed pro-
cedure before TPC insertion; however, a one-time diagnostic
thoracentesis was excluded. Operations performed for the
primary tumor were also not included in this definition.
Complications were graded according to the Clavien-
Dindo classification of surgical complications15 (grade I:
minor risk events not requiring therapy, grade II: requiring
pharmacologic interventions, grade III: requiring surgical or
radiological intervention, grade IV: life-threatening compli-
cation, and grade V: death).
Statistical Analysis
Overall survival was estimated at the patient level using
the Kaplan-Meier method, starting at the time of first catheter
insertion. All the remaining analyses were performed at the
catheter level. Time to catheter removal was estimated using
competing risk methodology, which accounts for the fact that
death is a competing event that precludes the possibility of
successful removal of the catheter. Comparisons of pleurode-
sis rates across patient, disease, and procedure-specific fac-
tors were performed using 2 tests, with the standard errors
adjusted through the Taylor series method to reflect the
potential clustering of two or more catheters within the same
patient. In addition, we performed subgroup analyses with the
above variables restricted to the lung and breast cancer
patients, the two largest cohorts in our series.
RESULTS
A total of 418 TPCs were placed in 355 patients during
the study period. Forty-two patients had a contralateral TPC,
13 patients had additional ipsilateral TPC, and 4 patients
underwent both a contralateral and an additional ipsilateral
TPC (a total of eight additional catheters). Patient demo-
graphic data and primary cancer types are shown in Table 1,
and breakdown by patient and catheter status is shown in
Figure 1. Median overall survival in our series from the time
of the first catheter insertion was 3.7 months (95% confidence
interval [CI]: 2.9–4.5 months), with a median follow-up of
2.4 months (interquartile range, 1.0–6.4 months). Median
time to catheter removal was not reached in the entire cohort;
for the 147 catheters removed, time of indwelling TPC
ranged from 1 to 315 days, with a median of 44 days.
Palliation with TPC
Of the 418 catheters inserted, 380 (91%) did not need
an additional effusion-directed procedure. The rate of suc-
cessful palliation was similar when we looked at catheters
inserted in patients who lived more than 30 days after catheter
insertion (287 of 322 insertions, 89%). Of the 38 catheters
that needed an additional effusion-directed procedure, 50%
had the procedure within 2 months and the rest within 9
months of the initial catheter insertion. A total of 45 addi-
tional procedures were performed—18 new TPCs (40%), 16
TABLE 1. Patient and Catheter Characteristicsa
Patient
Characteristics
Catheter
Characteristics
Age,b yr 63 (16–90) Laterality
Gender Right 253 (61)
Male 148 (42) Left 165 (39)
Female 207 (58) Previous procedure
Primary cancer Yes 69 (17)
Lung 106 (30) No 349 (83)
Breast 62 (17) Location
GYN 36 (10) IR 261 (62)
Urologic 24 (7) OR 107 (26)
Upper GI 21 (6) Bedside 37 (9)
Sarcoma 18 (5) Clinic 13 (3)
Lower GI 18 (5) Loculation
Hepatobiliary 18 (5) Loculated 110 (26)
Others 52 (15) Simple 308 (74)
Total 355 Total 418
a Values are given as n (%).
b Values are given as the median (range).
GI, gastrointestinal; GYN, gynecologic malignancies; IR, interventional radiology;
OR, operating room.
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chest tubes (36%), 9 VATS pleurodesis (20%), and 2 thora-
centeses (4%). Of these 45, 32 were performed for recurrence
of effusions (9 of which were for recurrence within 30 days
of catheter removal) and 13 for catheter-related complica-
tions—8 mechanical and 5 infectious.
SP with TPC
SP was achieved in 110 of 418 catheters (26%). How-
ever, many patients die soon after catheter insertion, which
precludes the chance of SP. When accounting for the com-
peting event of death, the probability that a patient will have
successful SP during the study time was 34%. Fifty percent of
the patients who achieved SP had their catheter removed
within 60 days. There was no significant difference in SP rate
by gender (p  0.59), laterality (p  0.71), previous proce-
dure (p  0.80), effusion characteristics (p  0.45), or
primary cancer site (26% in lung, 29% in breast, 37% in
ovarian, and 35% in sarcoma, p  0.42).
Rates of SP by Insertion Technique and
Effusion Characteristics
TPC placements were performed by interventional ra-
diologists (261 of 418, 62%), thoracic surgeons (107 of 418,
26%), or pulmonologists (50 of 418, 12%). Ultrasound was
routinely used by the pulmonologists, but their SP rate of
30% (15 of 50) was not statistically significant compared with
the rate of 26% (95 of 368) in which no ultrasound was used
(p  0.63). SP rate appeared to vary slightly based on the
location of TPC placement—IR 22% (58 of 261), OR 36%
(39 of 107), bedside 22% (8 of 37), and clinic 38% (5 of 13)
(p  0.05) (Table 2). This association of SP and location was
strongest when comparing patients selected for TPC insertion
in IR versus the OR (p  0.009). Notably, the higher SP rate
in the OR was attributable to loculated pleural effusions
(45% OR versus 18% IR, p  0.014) as compared with no
difference seen in simple effusions (33% OR versus 24%
IR, p  0.145).
Further investigation into the 107 TPCs placed in the
OR revealed that 38 were performed using VATS. In the
other 69 catheters, patients were taken to the OR due to
surgeon or patient preference (for patient comfort or addi-
tional procedures being performed in the OR such as port
placement), and a routine Seldinger technique was used under
intravenous sedation. The SP rate was increased in patients
undergoing TPC placement with VATS compared with
Seldinger technique (53% versus 28%, p  0.011) (Table 2).
The higher SP rate in the VATS group was accounted for by
a significant difference in the 29 loculated effusions (67%
VATS versus 21% Seldinger, p  0.009), whereas in the 78
simple effusions, this difference was not significant (43%
VATS versus 29% Seldinger, p  0.22).
Lung Cancer
A total of 120 TPCs were placed in 106 lung cancer
patients, with a median survival of 4.3 months (95% CI:
2.8–7.0 months) and a median follow-up of 2.5 months
(interquartile range: 0.3–7.4 months). Overall SP rate in this
TABLE 2. Spontaneous Pleurodesis Rates Analyzed by
Location (Left) and Technique of Insertion Among OR Group
(Right)
SP, spontaneous pleurodesis; IR, interventional radiology; OR, operating room;
VATS, video-assisted thoracic surgery.
TPC not removed
236 (271) 
65%
TPC removed
137 (147) 
35%
Effusion Recurred
36 (37)
9%
Alive with TPC
58 (62)
15%
Died with TPC
178 (209)
50%
Died within 30 days
of insertion
76 (96)
22%
No Additional
Procedure
6 (6)
1%
Additional
Procedure
30 (32)
7%
Spontaneous
Pleurodesis
106 (110)
26%
Total
355 (418)
FIGURE 1. Patient disposition.
Values given as number of patients
with TPCs in parentheses. Percent-
ages are out of total TPCs. TPC,
tunneled pleural catheters.
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cohort was 26%, and no statistically significant impact of age,
gender, smoking history, or laterality was noted. In this
cohort, however, a history of previous procedure was found
to be a predictor of a lower rate of SP (11% versus 28%, p 
0.04). Again, location of TPC insertion was found to impact
SP rate (38% in OR versus 15% in IR, p  0.005). As in the
overall cohort, this difference was accounted for by loculated
(57% in OR versus 11% in IR, p  0.005) as compared with
simple effusions (32% in OR versus 17% in IR, p  0.15).
Breast Cancer
A total of 76 TPCs were placed in 62 breast cancer
patients, with a median survival of 8 months (95% CI:
3.3–12.1 months) and a median follow-up of 3.6 months
(interquartile range: 0.4–9.1 months). Overall SP rate in this
cohort was 29%. None of the aforementioned factors, includ-
ing age (p  0.10), smoking history (p  0.49), laterality
(p  0.62), previous procedure (p  0.56), location of TPC
placement (p  0.58), or operative technique (p  0.36),
yielded a statistically significant impact on rate of SP.
Complications
We encountered 20 TPC-related complications (4.8%).
Using the Clavien-Dindo classification of surgical complica-
tions15 (see Patients and Methods section), these included 5
grade II and 15 grade III complications, with no grade IV or
V complications as well as no complications in TPCs placed
in a bedside setting (Table 3). Of the 20 complications, 10
were infections—4 cases of cellulitis and 6 cases of empy-
ema. All cellulitis cases were successfully treated with oral
antibiotics and did not require catheter removal. All cases of
empyema required catheter removal—replacement with chest
tubes or pigtail catheters in four and open drainage in two. Of
the six empyema cases, only one case was a loculated
effusion. One case of ipsilateral pneumothorax was treated
with oxygen supplementation and negative pressure suction
applied to the TPC drainage system. Mechanical complica-
tions included seven blockages and two dislodgements that
required removal of catheters in all cases and replacement in
eight—five with chest tubes or pigtail catheters and three with
new TPCs. Two of the replacements took place in the OR.
Alteplase was administered through the TPC for suspected
malfunction in a total of seven cases. Of these catheters, five
had more than 200 ml drainage 2 to 3 hours after alteplase
instillation (range, 225–600 ml).
DISCUSSION
Evolution of TPCs over the last decade demonstrates
both clinicians’ and patients’ mutual desire to use minimally
invasive, palliative techniques in MPE management. Cur-
rently, an estimated 39,000 TPCs are placed annually in the
United States (personal communication, IMS 3Q2009 Market
Data). As clinical decision making in MPE depends on many
factors—symptom relief, pleurodesis, safety, convenience,
length of hospital stay, and cost—it becomes essential for
physicians to understand these parameters for each of the
available modalities. In terms of cost, TPCs were shown to be
more cost-effective than talc pleurodesis on short term4 al-
though this advantage was not seen in patients living more
than 6 weeks in a recent cost-effective analysis study.16 Of
the other important parameters in MPE management, our
results highlight three parameters—palliative efficacy, SP
rate, and safety.
Because of the short life expectancy in MPE patients,
many physicians contend that the primary goal of therapy in
these patients should be palliation rather than pleurodesis. As
such, effective palliation, measured by control of symptoms
and avoidance of future procedures, is one of the most
important outcome measurements in MPE. In our series, 91%
of TPCs resulted in effective palliation, as strictly defined by
obviating the need for subsequent effusion-directed proce-
dures. Furthermore, this rate of palliation by TPC is equiva-
lent to chemical pleurodesis, as has been shown in a random-
ized study.5
More importantly, our series also highlights the safety
of TPC, which is particularly pertinent considering that talc,
the treatment of choice for achieving pleurodesis, is associ-
ated with acute respiratory distress syndrome (ARDS), with
reported incidence in the range of 1 to 9%.17,18 Complication
rates of TPC in published reports range from 6 to 22%,4–14
many of which are minor such as cellulitis and blockage of
catheter. In our series, the complication rate was 4.8% over-
all, with 1.2% requiring only pharmacologic intervention and
3.6% requiring surgical/radiologic intervention (Table 3). It is
important to note that in our bedside/clinic group (50 TPCs),
there was no reported complication. Although this may be
partially confounded by the bedside/clinic cohort having a
shorter median survival of 76 days (of the 50 patients in the
group, 21 died within the first 2 months, when most infectious
complications would be expected to occur), this finding
nonetheless demonstrates that bedside placement does not
increase infection risk. Another observation made in our
series is the fact that no TPC required intervention or removal
related to catheter-related pain. Because chest tube as well as
talc pleurodesis is associated with pain, this highlights yet
another merit of TPC.
In contrast to a high rate of palliation, the SP rate in our
series was 26%, considerably lower than the rate of 45.6% as
reported in a recent systematic review of TPCs.19 This is also
lower than the rates reported by Tremblay et al. (43%)8 and
Warren et al. (58%),11 the two largest studies (Table 4) for
which there are the following potential explanations. As one
of the key goals in treating MPE patients is palliation of
dyspnea and minimizing future effusion-directed procedures,
TABLE 3. Complications
IR OR Bed/Clinic Total
Grade II
Infection (superficial) 3 1 0 4
Pneumothorax 0 1 0 1
Grade III
Infection (deep) 2 4 0 6
Mechanical 5 4 0 9
Total 10 (3.8%) 10 (9.3%) 0 (0%) 20 (4.8%)
IR, interventional radiology; OR, operating room; Grade II, requiring pharmaco-
logic interventions; Grade III, requiring surgical or radiological intervention.
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we used a strict SP definition by including postremoval
follow-up criteria. While recurrence of effusion or additional
effusion-directed intervention after TPC removal was consid-
ered a complication in other studies,8,11 we considered these
patients to have failed SP. Also, as not all patients with mild
symptoms or fluid reaccumulation underwent additional pro-
cedures, we ensured true SP had occurred by also reviewing
clinic notes and radiographic images from postremoval fol-
low-up. This strict definition accounts for the fact that our
TPC removal rate is higher than the SP rate (35% versus
26%, a difference of 37 cases, in which the TPC was re-
moved, but no durable pleurodesis occurred, Figure 1). In
these 37 cases, the median time to documented recurrence
was 61 days (range: 20–212 days). In addition, while prior
studies have excluded patients not expected to live more than
30 days, we included all patients receiving TPC in our
review. In our series, 96 catheters (23%) were placed in
patients who died within 30 days of insertion (Figure 1).
Exclusion of these catheters would result in an SP rate of 34%
(109 of 322)—if we further expand our analysis to patients
living more than 3 months, an SP rate of 42% (98 of 235) was
observed. In addition, 64 patients are still alive with catheters
in place at the time of preparation of this article—these
patients may indeed still achieve SP—thus, if we exclude
these patients from the analysis, the SP rate increases to 42%
(109 of 259), a figure comparable to those of Tremblay et al.
and Warren et al. Nonetheless, our results highlight the fact
that TPCs are inferior at achieving pleurodesis compared with
talc pleurodesis, in which reported rates exceed 90%. Rather,
the merit of TPCs is in their ability to effectively palliate.
With regard to predictors of SP, Warren et al.11 have
reported that patients with breast and gynecologic malignan-
cies experienced higher SP. While cancer type was not a
significant predictor of SP in our series, effusion character-
istics and insertion technique showed intriguing associations.
A select cohort of patients with loculated effusions who had
TPCs placed intraoperatively using VATS experienced an
increased SP rate of 67% (15 of 29), which contributed to the
high SP rate of 53% (69 of 107) in the VATS cohort. On
review of the operative reports, these patients specifically
underwent lysis of adhesions or placement of the TPC con-
necting pockets of loculations. These observations suggest
that in situations where patients are taken to the OR for
VATS pleurodesis and the lung does not fully expand, sur-
geons’ effort at lysing adhesions or placing TPCs under
visual guidance can significantly increase the chance of SP by
TPC. Patients with simple effusions, on the other hand,
experienced similar SP rates regardless of where the TPC was
placed (OR, IR, or bedside/clinic) or the technique used.
Combined with our safety parameters, these observations
suggest that for simple effusions, bedside placement of TPC
achieve safety and SP comparable to IR and OR placement.
Our study has limitations inherent to many retrospective
studies. Patient selection for TPC placement and location of
placement are based on physician referral bias. Nevertheless,
with the range of primary cancers, different location of insertion,
and different health care personnel who inserted TPCs, including
physician assistants and residents in training, our largest series of
TPCs provides strong rationale to integrate TPC in the manage-
ment of MPE. Making an informed management decision in the
setting of a terminal condition such as MPE is a difficult task for
physicians, patients, and family members. The findings reported
in this study will equip clinicians and patients with better
knowledge and evidence to select the optimal modality in the
management of MPE.
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